Analgesic efficacy of tramadol in cats with naturally occurring osteoarthritis
Open Access
- 12 April 2017
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 12 (4) , e0175565
Abstract
This study aimed to (1) compare outcome assessments in normal and osteoarthritic cats and (2) evaluate the analgesic efficacy of tramadol in feline osteoarthritis (OA), in a prospective, randomised, blinded, placebo-controlled, crossover design. Twenty cats were included after clinical examination, blood work and full body radiographs were performed. In Phase 1, outcome assessments aimed to differentiate normal (n = 5; i.e. exempt of any radiographic and clinical sign of OA) from OA (n = 15) cats. In Phase 2, OA cats were treated twice daily with a placebo (PG: cornstarch 15 mg) or tramadol (TG: 3 mg/kg) orally for 19 days, with a 3-month washout period between treatments. Evaluations were performed in normal and OA cats at baseline and consisted of: 1) peak vertical force (PVF) after staircase exercise; 2) telemetered night-time motor activity (NMA); and 3) response to mechanical temporal summation (RMTS). After treatment, PVF, NMA and RMTS evaluations were repeated in OA cats. Data were analysed with mixed model methods with an alpha-threshold of 5%. Phase 1: 1) PVF (% of body weight; mean ± SD) was higher in normal (59 ± 10.5) than in OA cats (50.6 ± 5.7) (p = 0.005); 2) NMA (no unit) was not different between groups; 3) RMTS (number of stimuli; median (range)) was higher in normal [29.5 (23.5–30)] than in OA cats [14 (8.5–28)] (p < 0.0001). Phase 2: PVF, NMA and RMTS presented a treatment effect (p = 0.024, p = 0.008 and p = 0.018, respectively). No clinically important adverse-effects were observed. Outcome assessments such as kinetics (PVF) and evaluation of central sensitisation (RMTS) are discriminant of OA status. Mobility measured by NMA was not discriminant of OA status, however it increased in OA cats with tramadol treatment. Nociceptive hypersensitivity quantified by RMTS was evident in OA cats and was responsive to tramadol treatment.Keywords
Funding Information
- Morris Animal Foundation (D09FE-803A)
- Natural Sciences and Engineering Research Council of Canada (441651–2013)
- Natural Sciences and Engineering Research Council of Canada (RDCPJ 418399–2011)
- Natural Sciences and Engineering Research Council of Canada (RDCPJ 491953–2016)
- Canada Foundation for Innovation (9483)
- Canada Foundation for Innovation (24601)
- Morris Animal Foundation (D10-901)
This publication has 35 references indexed in Scilit:
- Retrospective Case—Control Study of the Effects of Long-Term Dosing with Meloxicam on Renal Function in Aged Cats with Degenerative Joint DiseaseJournal of Feline Medicine and Surgery, 2011
- Central sensitization: Implications for the diagnosis and treatment of painPain, 2011
- Improving Bioscience Research Reporting: The ARRIVE Guidelines for Reporting Animal ResearchPLOS Biology, 2010
- Evaluation of a Therapeutic Diet for Feline Degenerative Joint DiseaseJournal of Veterinary Internal Medicine, 2010
- Effects of tramadol hydrochloride on the thermal threshold in catsAmerican Journal of Veterinary Research, 2009
- Antinociceptive effects of tramadol and acepromazine in catsJournal of Feline Medicine and Surgery, 2008
- Pharmacokinetics of tramadol, and its metabolite O‐desmethyl‐tramadol, in catsJournal of Veterinary Pharmacology and Therapeutics, 2007
- Evaluation of Client-Specific Outcome Measures and Activity Monitoring to Measure Pain Relief in Cats with OsteoarthritisJournal of Veterinary Internal Medicine, 2007
- Feline osteoarthritis: a prospective study of 28 casesJournal of Small Animal Practice, 2006
- Ethical guidelines for investigations of experimental pain in conscious animalsPain, 1983